Abstract
Takayasu arteritis (TAK) is a subtype of the large-vessel vasculitis, affecting the aorta and its major branches. Although T cell-mediated autoimmunity is mainly involved in vascular inflammation, in recent years, accumulating evidence suggests the important role of B cells in the pathogenesis and effectiveness of B-cell-targeted therapy with rituximab (RTX), a chimeric anti-CD20 monoclonal antibody in refractory TAK. Herein, we report for the first time a case involving a 34-year-old man with TAK who was refractory to four different biologic agents, such as one selective T-cell co-stimulation modulator (abatacept), one anti-interleukin-6 receptor monoclonal antibody (tocilizumab), and two tumor necrosis factor-α inhibitors (infliximab and etanercept), but eventually achieved remission with RTX. He received a total of six courses of RTX, and doses of prednisolone and methotrexate were tapered without relapse. The current case provided further evidence to the potential role of RTX therapy in patients with refractory TAK, and its efficacy needs to be validated in a controlled trial.
Similar content being viewed by others
References
Kermani TA, Dasgupta B (2018) Current and emerging therapies in large-vessel vasculitis. Rheumatology (Oxford) 57:1513–1524. https://doi.org/10.1093/rheumatology/kex385
Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z (2011) Pathogenesis of Takayasu’s arteritis: a 2011 update. Autoimmun Rev 11:61–67. https://doi.org/10.1016/j.autrev.2011.08.001
Hoyer BF, Mumtaz IM, Loddenkemper K et al (2012) Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 71:75–79. https://doi.org/10.1136/ard.2011.153007
Inder SJ, Bobryshev YV, Cherian SM et al (2000) Immunophenotypic analysis of the aortic wall in Takayasu’s arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg 8:141–148
Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21:231–264
Nishino Y, Tamai M, Kawakami A et al (2010) Serum levels of BAFF for assessing the disease activity of Takayasu arteritis. Clin Exp Rheumatol 28:14–17
Wang H, Ma J, Wu Q, Luo X, Chen Z, Kou L (2011) Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. J Vasc Surg 53:174–180. https://doi.org/10.1016/j.jvs.2010.06.173
Hadjadj J, Canaud G, Mirault T et al (2018) mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G. Rheumatology (Oxford) 57:1011–1020. https://doi.org/10.1093/rheumatology/key017
Galarza C, Valencia D, Tobon GJ et al (2008) Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 34:124–128. https://doi.org/10.1007/s12016-007-8028-z
Ernst D, Greer M, Stoll M, Meyer-Olson D, Schmidt RE, Witte T (2012) Remission achieved in refractory advanced takayasu arteritis using rituximab. Case Rep Rheumatol 2012:406963. https://doi.org/10.1155/2012/406963
Walters HM, Aguiar CL, Macdermott EJ et al (2013) Takayasu arteritis presenting in the context of active tuberculosis: a pediatric case. J Clin Rheumatol 19:344–347. https://doi.org/10.1097/RHU.0b013e31829ce750
Caltran E, Di Colo G, Ghigliotti G et al (2014) Two Takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol 33:1183–1184. https://doi.org/10.1007/s10067-014-2506-5
Ahmed M, Mansoor S, Assad S et al (2016) Refractory case of Takayasu arteritis in a young woman: a clinical challenge. Cureus 8(11):e872. https://doi.org/10.7759/cureus.872
O’Connor MB, O’Donovan N, Bond U, Phelan MJ (2017) Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant. BMJ Case Rep 10:2017. https://doi.org/10.1136/bcr-2016-217313
Pazzola G, Muratore F, Pipitone N et al (2018) Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford) 57:1151–1155. https://doi.org/10.1093/rheumatology/kex249
Nakagomi D, Kronbichler A, Witte T, Mohammad AJ, Jayne DRW (2018) Comment on: rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford) 57:1309–1310. https://doi.org/10.1093/rheumatology/kex493
JCS Joint Working Group (2011) Guideline for management of vasculitis syndrome (JCS 2008). Japanese circulation society. Circ J 75:474–503
Kerr GS, Hallahan CW, Giordano J et al (1994) Takayasu arteritis. Ann Intern Med 120:919–929
Clifford A, Hoffman GS (2014) Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol 26:7–15. https://doi.org/10.1097/BOR.0000000000000004
Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417
Curtis JR, Westfall AO, Allison J et al (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55:420–426. https://doi.org/10.1002/art.21984
Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68:318–323. https://doi.org/10.1136/ard.2008.088351
Decker P, Olivier P, Risse J, Zuily S, Wahl D (2018) Tocilizumab and refractory Takayasu disease: four case reports and systematic review. Autoimmun Rev 17:353–360. https://doi.org/10.1016/j.autrev.2017.11.026
Acknowledgements
We would like to thank Editage (www.editage.jp) for English language editing.
Funding
None.
Author information
Authors and Affiliations
Contributions
TM provided patient’s management, performed the literature review, and wrote the manuscript; TI, KA, YF, YS, and HF were involved in the clinical management; TI, TS, YK, HS, and HH provided intellectual contributions; TI supervised the entire process from drafting the paper to submission of the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Informed consent
Written informed consent was obtained from this patient.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mutoh, T., Ishii, T., Shirai, T. et al. Refractory Takayasu arteritis successfully treated with rituximab: case-based review. Rheumatol Int 39, 1989–1994 (2019). https://doi.org/10.1007/s00296-019-04390-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-019-04390-w